JNP is a rarity among small cap pharmas in that they are cash flow positive.
grew revs by 24% in 2017
licensed its only approved drug to Merck and Allergan for upfronts and 10% royalties.
Pharma Services Division provides specialty engineering , trial manufacturing, consulting and incubating space to small pharma. This division grew revs by 32% from 2016.
owns 2 drug delivery platforms: * bio-adhesive delivery system * intravaginal ring (IVR)
developing 3 IVR drugs in the pipeline for out-licensing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.